Methods for treating and preventing infectious disease
AssigneesUniversity of Iowa Research Foundation, The United States of America, as represented by the Secretary, Dept. of Health and Human Services, Coley Pharmaceutical Group, Inc.
InventorsArthur M. Krieg, Dennis Klinman, Alfred D. Steinberg
Life of this patent
Estimating the term…
Abstract
Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation are disclosed. The sequences are also useful as a synthetic adjuvant.
Claims41
An isolated nucleic acid sequence containing at least one unmethylated CpG dinucleotide and having a formula:
- 5′N1X1CGX2N23′
- wherein at least one nucleotide separates consecutive CpGs;
- X1 is adenine, guanine, or thymine;
- X2 is cytosine or thymine;
- N is any nucleotide and N1+N2 is from about 0-26 bases with the proviso that N1+N2 does not contain a CCGG quadmer or more than one CCG or CGG trimer;
- and the nucleic acid sequence is from about 8-30 bases in length.
An isolated nucleic acid sequence containing at least one unmethylated CpG dinucleotide and having the formula:
- 5′NX1X2CGX3X4N 3′
- wherein at least one nucleotide separates consecutive CpGs;
- X1X2 is selected from the group consisting of GpT, GpG, GpA, ApT and ApA;
- X3X4 is selected from the group consisting of TpT or CpT;
- N is any nucleotide and N1N2 is from about 0-26 bases with the proviso that N1 and N2 does not contain a CCGG quadmer or more than one CCG or CGG trimer;
- and the nucleic acid sequence is from about 8-30 bases in length.
A method for treating a subject having an autoimmune or other CpG associated disorder by inhibiting CpG-mediated leukocyte activation comprising administering to the subject an inhibitor of endosomal acidification in a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.